February 10, 2016
Patients with a low ankle-brachial index, but without clinically recognized CVD, may experience lower major adverse CV events and mortality rates while on statin therapy, according to study findings published in the Journal of the American College of Cardiology.
Rafel Ramos, MD, PhD, of the Jordi Gol Institute for Primary Care Research in Girona, Spain, and researchers categorized 5,480 patients from the Catalan primary care system’s clinical database into two groups: statins nonusers or new users (first prescription or re-prescribed after at least 6 months). All of the patients had an ankle-brachial index of 0.95 or lower and no diagnosis of CVD. The patients’ mean age was 67 years and 44% were women. Diabetes and hypertension were prevalent diagnoses in this population. The median follow-up was 3.6 years.